S. Le Moulec

Type de document

Co-auteur

L. Zhao

D Vicente

M.M. van den Heuvel

P.K. Stockman

A. Smolin

F.A. Shepherd

J. Schneider

U. Scheuring

G. Robinet

N.A. Rizvi

N. Reinmuth

R. Raja

S Peters

R. Natale

K. Nakagawa

V. Moiseyenko

A. Luft

K.-H. Lee

E.S. Kim

B.W. Higgs

S.B. Goldberg

S, L Geater

E.B. Garon

M. Cobo

B.C. Cho

V.K. Chand

A.M. Boothman

S.J. Antonia

M.J. Ahn

Date

Source

Serveur académique Lausannois (1)

Mot-clé

thérapie (1) norme (1) danger (1) maladie (1) adulte (1) procès (1) survie (1) Treatment (1) Chemotherapy (1) Inhibitors (1) Death (1) Ci (Chinese poetry) (1) Therapeutics (1) Survival (1) Patients (1) Months (1) Metastasis (1) Human beings (1) Lungs--Cancer (1) Lungs (1) July (1) Immunoglobulins (1) Death (1) Chemotherapy (1) Cells (1) Cell death (1) Cancer--Treatment (1) Cancer (1) Blood--Analysis (1) Antineoplastic agents (1)

Documents écrit par S. Le Moulec (1) | parle de S. Le Moulec (0)

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.

N.A. Rizvi et al. (1 mai 2020)